Tenax Therapeutics, Inc. (NASDAQ:TENX – Get Free Report) was the target of a large decrease in short interest during the month of October. As of October 15th, there was short interest totalling 21,000 shares, a decrease of 27.8% from the September 30th total of 29,100 shares. Approximately 0.7% of the shares of the company are short sold. Based on an average daily trading volume, of 510,200 shares, the short-interest ratio is presently 0.0 days.
Tenax Therapeutics Trading Down 5.7 %
TENX stock traded down $0.28 during trading on Tuesday, reaching $4.59. 75,871 shares of the company’s stock were exchanged, compared to its average volume of 275,568. Tenax Therapeutics has a 1-year low of $2.77 and a 1-year high of $61.20. The company’s fifty day moving average price is $3.81 and its 200-day moving average price is $3.60.
Tenax Therapeutics (NASDAQ:TENX – Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) earnings per share for the quarter, topping the consensus estimate of ($1.99) by $0.16. As a group, research analysts expect that Tenax Therapeutics will post -6.62 EPS for the current year.
Analyst Ratings Changes
Read Our Latest Stock Analysis on Tenax Therapeutics
Tenax Therapeutics Company Profile
Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Recommended Stories
- Five stocks we like better than Tenax Therapeutics
- How to Invest in Insurance Companies: A Guide
- Is McDonald’s Stock a Smart Buy After Sell-Off and Earnings?
- Bank Stocks – Best Bank Stocks to Invest In
- QuantumScape: Solid State EV Batteries Nearing Commercialization
- How to Invest in Biotech Stocks
- MicroStrategy: Is This Bitcoin-Powered Stock a Buy or a Gamble?
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.